Filing Details

Accession Number:
0001493152-25-007031
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
4Life Research, LLC
Company:
Clene Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
4Life Research, LLC 0 314,523 3.7%
David Lisonbee 0 555,328 6.5%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The amounts reported consist of 199,844 shares of common stock and 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by 4Life Research, LLC, of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power. The convertible promissory notes include a provision limiting the issuance of common shares upon conversion, to the extent such conversion, together with the exercise of any warrants, would require stockholder approval under the rules or regulations of the Nasdaq Stock Market.


SCHEDULE 13G



Comment for Type of Reporting Person:  The amounts reported consist of: (a) 199,844 shares of common stock and 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by 4Life Research, LLC (reported on page 2 of this Schedule 13G), of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (b) 27,131 shares of common stock held by Legato Investments, LLC, of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (c) 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by La Scala Investments, LLC, of which David Lisonbee is the majority beneficial owner and chairman, and over which David Lisonbee may be deemed to have sole voting and dispositive power; and (d) 36,495 shares of common stock and 62,500 shares of common stock underlying warrants held by David Lisonbee in his own name. The convertible promissory notes include a provision limiting the issuance of common shares upon conversion, to the extent such conversion, together with the exercise of any warrants, would require stockholder approval under the rules or regulations of the Nasdaq Stock Market.


SCHEDULE 13G


 
4Life Research, LLC
 
Signature:/s/ David Lisonbee
Name/Title:David Lisonbee/Manager
Date:02/14/2025
 
David Lisonbee
 
Signature:/s/ David Lisonbee
Name/Title:David Lisonbee
Date:02/14/2025
Exhibit Information

The undersigned hereby agree that the statement on Schedule 13G/A to which this Agreement is attached shall be filed by 4Life Research, LLC on its own behalf and on behalf of David Lisonbee. Date: February 14, 2025 4LIFE RESEARCH, LLC By: /s/ David Lisonbee, Manager DAVID LISONBEE By: /s/ David Lisonbee